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Ltd. This is an open access article unAbstract Inactivation of the tumor suppressor p53 is the predominant pathogenetic event in
head and neck squamous cell carcinoma (HNSCC). The p53 pathway in HNSCC can be compro-
mised through multiple mechanisms including gene mutations, hyperactivation of endogenous
negative p53 regulators and by the human papillomavirus E6 protein. Inactivation of p53 is
associated with poor clinical response and outcome; therefore, restoration of the p53 signaling
cascade may be an effective approach to ablate HNSCC cells. Viral approaches to restore p53
activity in HNSCC have been well-studied and shown modest activity in clinical trials. Recent
work has focused on high-throughput screens and rational designs to identify and develop small
molecules to rescue p53 function. Several p53-targeting small molecules have demonstrated
very promising activity in pre-clinical studies but have yet progressed to the clinical setting.
Further development of p53 therapies, in particular chemical approaches, should be priori-
tized and evaluated in the HNSCC setting.
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Fig. 2 Small molecule-based therapeutics to modulate p53 in
HNSCC. Wildtype p53 is inactivated through MDM2 dysregula-
tion or exogenous HPVE6 oncogene in HNSCC. CH1iB and nat-
ural products, triptolide, Minnelide and curcumin, target the
HPVE6 oncogene to reactivate p53 in HPV-associated carci-
nomas including HNSCC. Nutlins and RITA block the p53-MDM2
interaction to reactivate p53 in HPV-negative HNSCC. PRIMA-1,
CP-31390, MIRA-1 and RETRA are chemical molecules that
restore the transactivation activity of mutant p53.
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Worldwide, head and neck squamous cell carcinoma (HNSCC)
is the sixth most common cancer with an annual incidence of
600,000 and an overall mortality rate of 50%e60%. In the
United States, 53,640 new cases were reported in 2013, ac-
counting for 3% of all cancers.1 All head and neck malig-
nancies appear to arise from the mucosal surfaces at various
sites, including the oral cavity, pharynx and larynx. Despite
their common histologic origin, HNSCC are heterogeneous in
behavior and genetics. The main risk factors for the devel-
opment of HNSCC include prolonged exposure to tobacco
products and alcohol. More recently, infection with human
papillomavirus (HPV) has emerged as amajor etiologic factor
for HNSCC.2 Survival in patients with HPV-associated HNSCC
is significantly better than for patients with HPV-negative
HNSCC.3,4 Though there is relatively good prognosis for pa-
tients with HPV-associated HNSCC, clinical outcomes for
HPV-negative HNSCC patients remain poor and has not
changed in the past 3 decades despite advances in clinical
management.5 A common genetic alterations that is indis-
pensable in both HPV-negative and HPV-associated HNSCC is
the inactivation of the tumor suppressor p53. In HPV-
negative HSNCC, inactivation of p53, either through muta-
tions or dysregulation of endogenous p53 regulators, is
believed to be one of the earliest genetic alterations to
predispose cells to initiate the tumorigenesis cascade.6,7 In
contrast, p53 is almost universally wildtype in HPV-
associated HNSCC, however, p53 function is compromised
by the HPV oncogene E6.2 Functional inactivation of the p53
pathway accounts for about 80% of HSNCC,6 therefore,
treatments targeting the restoration of p53 function in HPV-
negative and HPV-associated HNSCC as a therapeutic strat-
egy has received intense focus. In this chapter, p53-based
therapies for HNSCC will be reviewed. This will include
gene therapy to delivery wildtype p53, the development of
viruses designed to target carcinoma cells without functional
p53, small molecules to restore p53 function in mutant p53
carcinoma cells and small molecules to disrupt endogenous
or exogenous inactivation of wildtype p53 (Figs. 1 and 2).Adenovirus p53 gene therapy
The tumor suppressor p53 and its target genes are essential
regulators of cell cycle control and induction of apoptosis.
The p53 signaling cascade modulates cell cycle and DNA
repair to maintain the genetic integrity of cells. If irrepa-
rable DNA damages occur, p53 activates cellular apoptotic
pathways to eliminate genetically damaged cells.8 p53 is
one of the most common genetic alteration and mutationsWildtype
p53
Mutant 
p53
Ad-p53
ONYX-015
Fig. 1 Virus-based therapeutics to modulate p53 in HNSCC.
Adenoviral p53 (Ad-p53) and ONYX-015 therapies are not se-
lective and have activity against wildtype and mutant p53
HNSCC cells.occurs in up to two-thirds of HNSCC. p53 mutations in
HNSCC are also associated with resistance to cisplatin-
based chemotherapy and radiation resulting in inferior
prognosis compared to HNSCC patients with wildtype
p53.9,10 To overcome inactivating p53 mutations, an
approach to reintroduce wildtype p53 has been developed
in which an adenovirus is used as a vehicle to transport the
wildtype p53 gene into carcinoma cells.11 This live virus
could then selectively target and kill cancer cells. Adeno-
viral vector system was selected as an ideal approach for
gene therapy based on several key reasons. Adenovirus is
able to infect both dividing and quiescent cells and the
adenovirus genome remains episomal and does not inte-
grate in the host cells. In addition, high levels of the desired
transgene product can be achieved in host cells and large
scale manufacturing is possible with the adenoviral sys-
tem.12 Liu et al,13 was one of the first to incorporate the
wildtype p53 gene into a first generation adenoviral back-
bone (Ad-p53). In vitro studies with Ad-p53 virus demon-
strated that p53 transduction could induce apoptosis and
decrease cell proliferation in various carcinoma cell lines,
including HNSCC.13 Another group showed that introduction
of Ad-p53 into HNSCC cells containing mutated p53, sensi-
tized the tumor cells to radiation therapy.14 Impressively,
Ad-p53 virus was active in vivo and reduced tumor growth
in xenograft models of HNSCC.15
Based on these successful pre-clinical studies, several
clinical trials assessing the safety and efficacy of Ad-p53
were conducted in the HNSCC population. A Phase I clinical
trial using p53 adenovirus gene therapy, INGN 201, was
performed in 33 patients with recurrent HNSCC.16 INGN 201
was designed to be a replication-defective virion and con-
tained p53 cDNA in the El region of the virus. All enrolled
HNSCC patients had incurable disease with loco-regional
recurrence. INGN 201 was dose-escalated in log in-
crements from 106 to 109 plaque-forming units (pfu) and in
half-log increments from 109 to 1011 pfu, delivered via
70 M.R. Castellanos, Q. Panintratumor injections. All HNSCC patients received at least
one course of INGN 201 consisting of 6 total administrations
given three times per week (every other day) for 2 weeks.
Patients with resectable disease (nZ 15) received one full
course of injections pre-operatively followed by two addi-
tional; one during surgery after tumor resection in the site
of microscopic residual disease and one 72 h after surgery
via retrograde catheter instillation. In this resectable
cohort, 27% of HNSCC patients remained disease-free with a
median follow-up time of 18 months. Of the 17 patients
with non-resectable disease, 2 patients responded with a
greater than 50% reduction in tumor size by CT scan, 6
patients had stable disease and 9 patients had disease
progression. However, the duration of stable disease in
these six patients was very modest and only lasted 1e3.5
months. Multiple courses of direct intra-tumoral injections
of INGN 201 were well tolerated with no dose-limiting
toxicity or serious adverse events. Injection site pain was
the most common reported adverse event and resolved
within 24 h p53 expression was detected in post-treatment
tumor biopsies providing proof of principle that adenoviral
delivery of wildtype p53 to HNSCC tumors can be achieved
with a safe toxicity profile.
Different schedules of viral gene therapy were evaluated
in Phase II trials to determine the optimal intratumoral dose
of p53 adenoviral therapy in HNSCC. In the T201 trial, doses
ranged from 5  1010 viral particles (vp) to 2.5  1012 vp
with a median dose of 1.2  1011 vp.17 HNSCC patients were
stratified to two cohorts with different dosing schedules;
one group received 3 doses every 28 days and another group
received 6 doses in 28 days. Objective response was only
reported in 6 out of 106 enrolled patients in both cohorts. In
another Phase II trial, using a starting dose that was 50
times less than used in the T201 study, 20% of the high-dose
cohort demonstrated a durable response of greater than 3
months compared to 14% of patients in the low-dose
cohort.17 The median survival was 6 months versus 3.5
months and mortality was reported as 60% versus 40% at 150
days in the high-dose and low-dose cohorts, respectively.
Both studies concluded that p53 adenoviral therapy was
safe and well-tolerated.
In a Phase III randomized clinical trial, 116 patients with
recurrent HNSCC were enrolled and treated with Ad-p53
gene therapy or methotrexate.18 Study endpoints included
p53 biomarkers profiles to determine favorable versus un-
favorable characteristics and which type of HNSCC patients
would respond to therapy. Interestingly, this study found
that most of the responders to Ad-p53 therapy had wild-
type p53 in which p53 was inactivated by overexpression of
the p53 inhibitors MDM2/MDM4 or had low expression of
mutant p53. HNSCC patients with the favorable p53 profile
had a significant increase in survival compared with pa-
tients with an unfavorable p53 profile (high expression of
mutant p53). Survival for patients with a favorable p53
profile was 7.2 months compared to 2.7 months in the
unfavorable p53 profile group (P < 0.0001). In contrast,
most patients with response to methotrexate (87%) had
high expression of mutated p53. The authors concluded
that there was no significant difference in clinical benefit
between patients treated with Ad-p53 and methotrexate;
however, Ad-p53 therapy may be less toxic than
methotrexate.Virus that targets p53-deficient carcinoma
cells
Another viral approach that has been evaluated is the de-
livery of a modified adenovirus that preferentially targets
p53-deficient carcinoma cells. It is well documented that an
active p53 signaling pathway negatively regulates the repli-
cation of adenoviruses. Adenoviruses evade this negative
control mechanism by producing the E1B protein to bind and
inactivate wildtype p53 function in infected host cells.19
ONYX-015 is a chimeric virus consisting of 2 species C ade-
noviruses genomes, serotypes 5 (Ad5) and serotype 2 (Ad2).
This virus was designed to not express E1B. As a result of this
deletion, ONYX-015 was proposed to efficiently replicate in
and lyse p53-deficient cell, while not affect cells containing
wildtype p53. Two studies confirmed that ONYX-015 induced
lysis in p53 mutant carcinoma cells after exposure, in a
replication-dependentmanner, both in vitro and in vivo.20,21
These studies demonstrated the selective destruction of
cancer cells, however, it was later found that ONYX-015 had
anti-tumor activity against tumor cells that expressed wild-
type p53, via a unknown mechanism.22
Despite the contradictory pre-clinical data, the efficacy
of ONYX-015 as monotherapy or in combination of standard
chemotherapeutics was assessed in HNSCC patients. A Phase
I trial was initiated to evaluate intratumoral ONYX-015 in
recurrent HNSCC patients.23 p53 status was assessed in all
the patients enrolled (nZ 22); 16 patients hadmutant p53, 5
patients had wildtype p53 and 1 patient could not be cate-
gorized. Overall, intratumoral injection of ONYX-015 was
well-tolerated with no dose-limiting toxicity observed. Dose
escalation was halted due to limitation of virus
manufacturing capacity encountered during the active pa-
tient recruitment phase. In any event, viral doses were
escalated to 1  1011 plaque-forming units (pfu) given daily
once every 3 weeks or 1  1010 pfu for 5 consecutive days
every 3 weeks. The most frequent symptoms were low grade
fever and pain at the injection site. One patient experienced
grade 2 symptoms of tracheal obstruction that may be
attributable to ONYX-015. All patients in the study pro-
gressed; however, it should be noted that all tumorswere not
injected with ONYX-015 in each patient. To account for this
study design limitation, data was evaluated only on tumors
that received ONYX-015. A common finding was that the
injected tumor became soft and fluctuant after treatment.
One patient had a 50% decrease in the size of the tumorwhile
another showed a 75% reduction in the size of the tumor by
radiological imaging. These preliminary results show that
intratumoral administration of ONYX-015 is feasible, well
tolerated and associated with some biological activity.
However, there was no association between tumor response
and tumor p53 status in this Phase I study cohort.
A Phase II trial in recurrent or refractory HNSCC patients
that received conventional therapy (nZ 40) was performed
to further evaluate the clinical activity of ONYX-015.24 For
each patient, a single tumor was identified for intratumoral
ONYX-015 treatment. If more than one possible injectable
tumor was seen the most symptomatic and/or largest lesion
was treated with ONYX-015. For the initial phase of the
study, tumor injections were performed once daily for 5
consecutive days (standard schedule) then repeated every 3
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safety with the standard treatment regimen with the first 30
patients, a more aggressive hyperfractionated schedule was
performed on the next group of patients. For the second
cohort of patients, injections were performed twice daily for
5 days during each of the first 2weeks, the same regimenwas
repeated after a 1-week rest period and subsequently,
maintenance treatment was given every 3 weeks. In the
standard dosing group, 4 patients (14%) achieved a partial or
complete regression at the injection site, 12 (41%) had stable
disease, and 13 (45%) progressed. In the hyperfractionated
patients, 1 patient had complete regression, 4 (58%) ach-
ieved stable disease, and 2 (29%) progressed. In contrast to
the Phase I study, a correlation was demonstrated between
tumor response and mutant p53 status.
In vitro and in vivo pre-clinical data provided compelling
evidence that ONYX-015 potentiated the anti-tumor effi-
cacy of standard chemotherapeutics.20 Based on these
findings, two studies evaluated the combination of ONYX-
015 with cisplatin/5-flurouracil (5-FU) in the recurrent
HNSCC setting.25,26 Khuri et al reported that the combina-
tion regimen was highly active and reduced the size of tu-
mors in 25 out of the 30 cases. Objective response, with a
decrease of 50% or more in tumor size, was reported in 63%
of patients with injected tumors. The addition of ONYX-015
to cisplatin/5-FU was suggested to be highly beneficial
since the overall injected-tumor response rate observed
was superior to published data from multi-center, ran-
domized trials evaluating cisplatin/5-FU in HNSCC. How-
ever, similar to the Phase I trial, no correlation between
tumor response and tumor p53 status was reported in this
Phase II combination regimen trial.
These reports show that ONYX-015 had limited effects
when used alone, however, a select group of patients
receiving ONYX-015 combined with chemotherapy did bet-
ter than standard treatment alone. Identifying such pa-
tients was not completely clear. Analysis of the data
showed that p53 selectivity did not always occur. Some
patients with wild type p53 did better than patients with
mutant p53 tumors. As a result of these findings in US based
clinical trials and funding issues of the manufactures of
ONYX-015, continued Phase III studies were stopped. The
technology was licensed to a Chinese company that modi-
fied ONYX-015 to form another oncolytic adenovirus H101
(Oncorine).27 In Phase III clinical trials done in China,
Oncorine plus chemotherapy was reported to have 79%
response rate in nasopharyngeal carcinoma compared 40%
with chemotherapy alone.28 In 2005, H101 received
approval in China for treatment of nasopharyngeal cancer.
Though this a milestone for the development of oncolytic
virus, limitations still occur due to the fact that both ONYX-
01529 and H101 have to be given intratumor and both vi-
ruses have not been able to be given systemically.
Continued research into oncolytic therapy may be able to
overcome these issues using other viruses instead of
adenoviral vectors.29Molecules that target mutant p53
Mutations in p53 are a frequent event and occur in about
two-thirds of all HNSCC cases. p53 mutations arepredominantly localized in the DNA binding domain which
effectively block mutant p53 from binding to response el-
ements of transactivate target genes. Considerable effort
has been made to discover molecules that can alter and
stabilize the 3-dimensional confirmation of mutant p53 to
restore function. A screen using a library of >100,000
compounds identified CP-31398 as a small molecule which
enhanced the conformational stability of the DNA binding
domain in wildtype and mutant p53.30 CP-31398 was shown
to enhance the transcriptional activity of mutant p53 and
induce the p21, a p53-regulated gene, levels in Saos-2
osteocarcinoma cells expressing V173A or R249S mutant
p53.30 Moreover, in vivo tumor growth of p53 mutant car-
cinoma cells, A375.S2 melanoma (249 mutation) and DLD-1
colon carcinoma (241 mutation), were retarded with sys-
temic delivery of CP-31398.30 Another molecule, p53
reactivation and induction of massive apoptosis (PRIMA-1),
was identified from a chemical library screen to selectively
inhibit the proliferation of cells in a mutant p53-dependent
manner.31 Impressively, PRIMA-1 restored the ability of a
cadre of p53 mutants to bind to DNA confirming that PRIMA-
1 can modify the 3-dimensional confirmation of mutant
p53.31 PRIMA-1 was reported to be degraded to reactive
products with thiol-modifying activity.32 These reactive
products form adducts with thiols on one or several
cysteine residues in the core domain of mutant p53 to
restore p53 function.32
The anti-tumor activity of CP-31398 and PRIMA-1 has
been widely studied in a wide variety of carcinomas over
that past decade. However, to date, only one study has
examined the response of HNSCC cells to these two mutant
p53 modifying molecules. In a small panel of wildtype and
mutant p53 HNSCC cell lines, CP-31398 and PRIMA-1 was
shown to be more active in three mutant p53 HNSCC cell
lines than in a wildtype p53 HNSCC cell line.33 The combi-
nation regimen of PRIMA-1 and cisplatin was more active
than either single-agent treatment to induce the levels of
p53-regulated pro-apoptotic genes, p21, Bax, PUMA and
NOXA and suppress cell proliferation in p53 mutant (Y220C)
UMSCC22A HNSCC cells.33 To improve on the activity of
PRIMA-1, Bykov et al synthesized PRIMA-1 analogs and found
that a methylated analog of PRIMA-1, PRIMA-1MET, was more
active than PRIMA-1 to block the proliferation and induce
active caspase-3 in mutant p53 cells.34 The anti-tumor ef-
ficacy of cisplatin was potentiated with PRIMA-1MET in
mutant p53 (H175) H1299 lung carcinoma cells in vitro and
in vivo.34 In addition, PRIMA-1MET cooperated with cisplatin
to induce Bax and PUMA in a mutant p53-dependent
context.34 The development of PRIMA-1MET has progressed
rapidly and a Phase Ib/II clinical trial opened in 2014
(NCT02098343) to study PRIMA-1MET as single-agent or in
combination with a platinum-based chemotherapeutic in
recurrent ovarian carcinoma. Since PRIMA-1MET is already in
clinical development, pre-clinical studies to assess the ac-
tivity of PRIMA-1MET in HNSCC in vitro and in animal models
should be prioritized in the near future.
Although PRIMA-1 and PRIMA-1MET were shown to restore
mutant p53 function, there is accumulating experimental
evidence that these molecules have p53-independent anti-
tumor activity. PRIMA-1 induced autophagy in wildtype and
mutant p53 carcinoma cells.35 Two different groups
demonstrated that the anti-tumor effect of PRIMA-1MET in
72 M.R. Castellanos, Q. Panmultiple myeloma was due primarily to induction of p73 or
modulation of the glutathione/reactive oxygen species
balance.36,37 These findings indicate that PRIMA-1 and
PRIMA-1MET have multiple mechanisms of action and suggest
that these molecules should not be limited to the mutant
p53 setting.
Other novel mutant p53 reactivation molecules, such as
mutant p53 reactivation and induction of rapid apoptosis
(MIRA-1) and reactivation of transcriptional reporter ac-
tivity (RETRA), have been developed but have not been
studied in HSNCC. MIRA-1 was identified using the same
screening approach as PRIMA-1; selective cell proliferation
inhibition in mutant p53 cells.38 MIRA-1 altered the 3-
dimensional conformation of a small set of p53 mutants
to restore DNA binding to the consensus p53 response
element.38 It should be noted that MIRA-1 was not as robust
as PRIMA-1 and only restored DNA binding to 3/13 p53
mutants whereas PRIMA-1 restored DNA binding to 10/13
mutants.31,38 A high-throughput p53 reporter activity
screen showed that RETRA selectively restore p53 activity
in p53 mutant (H273) A431 lung carcinoma cells.39 RETRA
enhanced p53 transcriptional activity in a panel of carci-
noma cells lines with various p53 mutations including
R273H, R248W, G266E and R280L.39 Interestingly, the pri-
mary mechanism of action for RETRA was not to restore
mutant p53 function but rather to release p73 sequestered
by mutant p53 to augment p73 activity.39 The finding sug-
gests that activation of p53 family members, such as p73,
may be an alternative therapeutic strategy to ablate
mutant p53 carcinoma cells.Molecules that target negative endogenous p53
regulators
p53 is dynamically and tightly controlled by endogenous
p53 regulators to modulate p53 function in response to
diverse cellular conditions. Mouse double minute 2 homolog
(MDM2) is the prototypical negative p53 regulator and can
suppress p53 through several distinct mechanisms. MDM2
binds to and masks the transactivation domain of p53 to
repress p53 transcriptional activity. In addition, MDM2
functions as an E3 ubiquitin ligase to mark p53 for degra-
dation through the ubiquitin-proteasome pathway.40 MDM2
levels are elevated in numerous solid malignancies,
including HNSCC, and thus, rescue of p53 function by tar-
geting the p53-MDM2 interaction may be an effective
approach to eliminate wildtype p53 carcinoma cells.
A class of small molecules, nutlins, was identified from a
diverse chemical library to displace the binding of wildtype
p53 from MDM2 with high potency and selectivity.41 Nutlins
bind to the p53-binding pocket of MDM2 to stabilize p53
resulting in p53 pathway activation in wildtype p53, but not
in mutant p53, carcinoma cells.41 Another research group
identified reactivation of p53 and induction of tumor cell
apoptosis (RITA) from a cell-based screen to selectively
inhibit the growth of wildtype p53 HCT116 carcinoma cells
in comparison to the isogenic p53 null HCT 116 carcinoma
cells.42 RITA directly binds to the N-terminal domain of
wildtype p53 and is postulated to induce a conformational
change in wildtype p53 to prevent association with MDM2.42
Wildtype p53 carcinoma cells treated with RITA had anincrease in p53 accumulation and activity and moreover,
high expression of p53 target genes, GADD45a and PUMA.42
In a panel of wildtype and mutant p53 HNSCC cell lines,
nutlin-3 and RITA were found to be more active in wildtype
p53 HNSCC cells than in mutant p53 HNSCC cells.33 Nutlin-3
and RITA increased p53 accumulation and apoptosis and
potentiated the anti-tumor efficacy of cisplatin in wildtype
p53 JHU-028 HNSCC cells.33,43
Recent evidence indicates that p53-MDM2 proteinepro-
tein inhibitors (PPIs), such as nutlins and RITA, have anti-
tumor activity in the setting of mutant or null p53. RITA was
shown to induce senescence in HNSCC cells in a p53-
independent mechanism.44 In mutant or null p53 HNSCC
cells, RITA promoted senescence through inhibition of si-
lent information regulator T1 (SIRT1), a histone deacetylase
recognized as a negative regulator of cellular senes-
cence.44,45 Moreover, RITA augmented that activity of
tenovin 6, a SIRT1 inhibitor, and radiation in mutant p53
HN31 HNSCC cells.44 Another study showed that nutlin-3
augments chemotherapy-induced apoptosis in mutant and
null p53 carcinoma cells by releasing E2F1 from the E2F1-
MDM2 complex.46 Also, nutlin-3 was reported to disrupt
p73-MDM2 interaction to enhance p73 activity in mutant
p53 SK-N-BE2 neuroblastoma and null p53 Saos-2 osteosar-
coma cells.47 These results provide initial evidence that
nutlin-3 and RITA may have clinical utility as part of a
combination regimen in mutant p53 HNSCC cells.Molecules that target negative exogeneous p53
regulators
The traditional risk factors for HNSCC are alcohol and to-
bacco abuse. However, there is ample evidence that the
human papillomavirus (HPV) is an etiological factor for
HNSCC, particularly oropharyngeal SCC. HPV16 is the most
prevalent subtype and accounts for w90% of HPV-
associated HNSCC.48,49 Epidemiological data indicate that
the prevalence of HPV-associated HNSCC has increased by
w3-fold in the past three decades in the United States and
Europe.50e52 Data obtained from the Swedish Cancer Reg-
istry showed a 2.8-fold increase in the incidence of
oropharyngeal SCC in the Stockholm area between 1970 and
2002. Interestingly, over the same time period, the inci-
dence of HPV-associated oropharyngeal SCC increased by
w3-fold from 23% in the 1970s to 68% in the 2000s.53 Based
on these alarming numbers, it has been suggested that an
epidemic of HPV-associated HNSCC will emerge in the near
future.52,53 HPV-associated HNSCC patients are often
managed with radiation or concurrent platinum-based
chemoradiation. These strategies are effective against
HPV-associated HNSCC but come at a cost of high patient
morbidity. Molecularly-targeted therapies that ablate HPV-
associated HNSCC with better toxicity profiles are critically
needed to manage this growing patient population.
In HPV-associated HNSCC, p53 is almost universally
wildtype but inactivated by the HPV oncogene E6. HPVE6
forms a trimeric protein complex with E6AP and p53 to
facilitate E6AP-mediated ubiquitination and degradation of
p53 through the proteasomal pathway.54,55 In addition to
promoting p53 degradation via the proteasome, a less
recognized but perhaps more important mechanism is that
Novel p53 therapies 73HPVE6 can bind to the p300 transcriptional co-activator to
sequester p300 function. Several lines of evidence indicate
that HPVE6 associates with p300 to inhibit p300-mediated
p53 acetylation.32,56,57 Acetylation controls p53 function
at multiple levels including enhancing p53 stability, tetra-
merization, DNA binding and co-activator recruitment.58e60
Since inactivation of p53 by HPVE6 is indispensable for HPV-
mediated tumorigenesis, targeting the HPVE6-p300 inter-
action may be a novel molecular approach to reactivate p53
and ablate HPV-associated carcinoma cells. Several lines of
evidence show that HPV16E6 binds to the CH1 domain of
p300.57,61 Therefore, CH1-like ligands may serve as
competitive inhibitors to mask the HPV16E6 binding site on
p300 and disrupt HPV16E6-p300 interaction in HPV-
associated HNSCC. A rationally designed small molecule
CH1 ligand, CH1iB, blocked the HPV16E6-p300 interaction
and reactivated the p53 pathway in HPV16-associated
HNSCC cell lines, UMSCC47 and UPCI-SCC090.62 CH1iB
induced the expression of p53-regulated genes, p21, miR-
34a and miR-200c, promoted a pleotropic anti-tumor ef-
fect and potentiated the efficacy of cisplatin in HPV16-
associated HNSCC cells.62 These results demonstrate that
targeting the HPV16-p300 interaction is a fresh and trac-
table approach to reactivate p53 in HPV16-associated
HNSCC.
Several anti-cancer natural products have been reported
to degrade HPVE6 and/or reactivate p53 in HPV-associated
carcinoma cells. Triptolide, a derivative from the Chinese
herb Tripterygium wilfordii, reduced HPV16E6 expression
and increased p53 levels and transcriptional activity in
HPV16-associated UMSCC47 and 93-VU-147 HNSCC cells.63 In
a HPV16-associated HNSCC xenograft animal model, a
water-soluble analog of triptolide, Minnelide, enhanced
p53 activation, inhibited tumor growth and increased
apoptosis.63 The major yellow pigment from the rhizomes
of turmeric, curcumin, reduced HPVE6 levels and induced
p53 accumulation in HPV16- and HPV18-associated cervical
carcinoma cells.64e66 Curcumin sensitized HPV-associated
cervical carcinoma cells to radiation through an increase
in reactive oxygen species production.67 Another laboratory
showed that curcumin failed to sensitize HPV-associated
HNSCC cells to radiation suggesting that the radiosensitiz-
ing actions of curcumin may be cell type-dependent.68
Interestingly, in silico docking analysis revealed that
several natural products, including curcumin, have the
potential to dock to the p53-binding site of E6, however,
with varying binding affinities.69 The natural products,
carrageenan (sulfated polysaccharide extracted from red
algae) and withaferin A (active component of the medicinal
plant Withania somnifera), have much higher binding af-
finities than curcumin and interacts with amino acids Ala53,
Leu117 and Lys122 in the E6 p53-binding pocket.69 Carra-
geenan and withaferin A have not been evaluated in HNSCC
and work should be performed to determine the activity
and mechanism of action of these two natural products for
HPV16-associated HNSCC.Conclusion
The standard of care to manage HPV-negative and HPV-
associated HNSCC patients has evolved over the years andcurrently consists of a multi-disciplinary treatment
approach, including surgery, radiation and/or chemo-
therapy. Despite treatment advances, the clinical outcome
of HPV-negative HNSCC remains dismal and has not changed
in the past several decades. HPV-associated HNSCC patients
respond well to the standard of care; however, this intense
treatment regimen is difficult to tolerate and associated
with high morbidity. Novel therapeutic strategies, with
higher efficacy and lower toxicity, are needed to better
manage the HPV-negative and HPV-associated HNSCC
population.
Since loss of p53 function is the predominant pathoge-
netic event in HNSCC, restoration of p53 activity may be an
optimal approach to eliminate HNSCC cells with high
specificity. Adenoviral therapeutic strategies, such as Ad-
p53 and ONYX-015, have progressed to clinical trials in the
HNSCC setting but have shown modest activity. In addition
to limited clinical activity, there are several issues that
argue against additional research investment into these
two adenoviral therapies. One major limitation of Ad-p53
and ONYX-015 is the requirement of repeated intratumoral
injections into each tumor lesion and thus, the adoptability
and availability of these two therapies may be limited to
major academic centers. Another confounding issue with
Ad-p53 and ONYX-015 is target cell specificity. Ad-p53 was
designed to target mutant p53 carcinoma cells; however,
data from a Phase III clinical trial indicate that Ad-p53 is
more active in the wildtype but inactivated p53 setting.
Similarly, ONYX-015 is non-selective and has activity in both
wildtype and mutant p53 HNSCC. Recent work has focused
on chemical approaches to restore p53 function in HPV-
negative and HPV-associated HNSCC. Several of these
molecules, such as PRIMA-1 for HPV-negative HNSCC and
CH1iB for HPV-associated HNSCC, have shown very prom-
ising activity in the pre-clinical realm but has yet to be
proven in the clinical setting. Additional resources to fast-
track the development of chemical molecules that restore
p53 function in HPV-negative and HPV-associated HNSCC is
warranted and should be prioritized in the near future.
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